Ondansetron a widely prescribed anti-ulcer drug belongs to BCS class II and exhibit low and variable oral bioavailability due to its poor solubility and dissolution rate and having high permeation rate. In the present work, oral disintegrating tablets of Ondansetron were developed with a view to enhance the patient compliance and provide quick onset of action. Ondansetron is a serotonin 5-HT3 receptor antagonist used mainly as an anti-emetic (to treat nausea and vomiting). It affects both peripheral and central nerves. Ondansetron reduces the action of the vagus nerve, which deactivate the vomiting centre, and also block serotonin receptors in the chemoreceptor trigger zone. It has slight effect on vomiting caused by motion sickness, since drug is highly bitter. The drug solid dispersed coated granules showed no bitterness in the taste. Oral disintegrating tablets prepared by direct compression method using super disintegrants like cross povidone, cross carmellose sodium, sodium starch glycolate, in different concentrations and evaluated for the pre-compression parameters such as bulk density, compressibility and angle of repose. The arranged batches of tablets were evaluated for hardness, weight variation, thickness, friability, drug content, disintegration time and invitro dissolution profile and found satisfactory. Aim: The aim of the present study is to formulate and evaluate fast disintegrating tablets of Ondansetron by direct compression method employing super disintegrating agents. The objective of present study: • The purpose of this research was to mask the strongly bitter taste of Ondansetron HCL and to formulate a rapid - disintegrating tablet. • To formulate an orally disintegrating tablet so that it can be administered to paediatric and geriatric patients.
Comments: 7 Pages.
[v1] 2017-08-23 05:09:58
Unique-IP document downloads: 213 times
Vixra.org is a pre-print repository rather than a journal. Articles hosted may not yet have been verified by peer-review and should be treated as preliminary. In particular, anything that appears to include financial or legal advice or proposed medical treatments should be treated with due caution. Vixra.org will not be responsible for any consequences of actions that result from any form of use of any documents on this website.
Add your own feedback and questions here:
You are equally welcome to be positive or negative about any paper but please be polite. If you are being critical you must mention at least one specific error, otherwise your comment will be deleted as unhelpful.